Introduction
In the 1980s, two heavily-glycosylated proteins were discovered as potential markers for breast and epithelial ovarian cancer(EOC)(1, 2). Monoclonal antibodies were raised against selected epitopes and assays developed whose names became synonymous with the markers CA15.3 for the breast biomarker and CA125 for the EOC biomarker. Genes for these proteins were eventually cloned and proved to be members of the human mucin family(3, 4) -CA15.3 as human mucin 1 (MUC1) and CA125 as human mucin 16 (MUC16). Both proteins were found to be expressed on mucosal barriers lining the genital, digestive, and respiratory tracts and breast ducts and over expressed in many of the neoplasms originating from these tissues (5, 6).
Specifically, for invasive EOC and depending upon the antibody used for histochemical analysis, a majority of all EOC subtypes express CA15.3(7). Tissue expression of CA125 varies by subtype from 12% (mucinous) to 85% (serous)(8). Higher serum levels of CA15.3 in patients with breast and colorectal cancers were associated with poorer prognosis(9, 10) and thought to reflect an immunosuppressive effect on T cell proliferation(11). Similarly, in EOC, high serum levels of CA125 predict advanced disease and poorer survival(12). Like CA15.3, this may have an immune basis since CA125 can bind with natural killer(NK) cells and blunt NK response to ovarian tumors cells(13).
Antibodies against CA15.3 and CA125 have also been described. Anti-CA15.3 antibodies were found in some in patients with CA15.3-expressing cancers and associated with better prognosis (14) . Both CA15.3 and anti-CA15.3 antibodies can also be found in healthy women, including those who are pregnant or breastfeeding (15) . This led to the theory that anti-CA15.3 antibodies evoked by these events could explain why they protect against breast cancer(16). CA125 is elevated in pregnancy, but whether anti-CA125 antibodies also form during pregnancy has not been studied. However, events which reduce EOC risk like pelvic surgery, mumps, or puerperal mastitis, may lead to elevated (and presumably protective) levels of both anti-CA125 and anti-CA15.3 antibodies (17) (18) (19) (20) . Conversely, chronic events that increase EOC risk like repeated damage and repair to the ovary from "incessant ovulation" (ovulations not interrupted by pregnancy or oral contraceptive use) were associated with lower levels of anti-CA15.3 antibodies, suggesting immune tolerance that allows emergence of a CA15.3-expressing cancer (20, 21) . These observations form the basis for a general paradigm that risk factors for mucin-expressing cancers may operate because of humoral (and, likely, cellular) immune reactions to mucin-expression invoked by the events themselves. Chronicity of the exposure may determine whether the event raises or lowers risk for the cancer.
In this study, we measured anti-CA15.3 and anti-CA125 antibodies and their corresponding antigens in sera from female participants in the European Prospective Investigation of Nutrition and Cancer(EPIC) including 806 who subsequently developed invasive EOC and 1,927 matched controls. We sought to identify factors associated with levels of anti-CA15.3 and anti-CA125 antibodies by menopausal status and determine whether these antibodies were associated with early detection (elevated levels within three years of diagnosis) or risk (elevated levels three or more years before diagnosis) of EOC overall and by histologic subtypes.
Material and Methods

The EPIC cohort -background and collection of blood samples
EPIC is an ongoing multicenter prospective cohort study designed to investigate relationships between diet and cancer (22) . Briefly, 519, 978 participants (366, 521 women) were enrolled from 1992 to 2000 in 23 centers in 10 European countries: Denmark, France, Germany, Greece, Italy, Norway, the Netherlands, Spain, Sweden, and the United Kingdom. A total of 385,747 participants (226,673 women) provided a baseline blood sample, kept frozen in long-term storage at ≤-150 o C, with the exception of Sweden, where samples are stored at -70 o C.
Ascertainment of incident cancer cases
Cancer occurrence was documented through record linkage with cancer registries or active follow-up. Self-report was verified by clinical record review. Vital status was determined by linkage with mortality registries. When the present study was initiated, follow-up was complete 
Design of nested case-control study
For each case, up to four controls were randomly selected from female cohort members who were alive and cancer-free at diagnosis of the index case using a sampling protocol described previously(23). Case and control participants were matched on study center, age at blood donation, time of the day of blood collection, fasting status, menopausal status, menstrual cycle phase for premenopausal women, current use of oral contraceptives(OC) or hormonal replacement therapy (HRT).
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Exposure Data
Baseline data were self-reported through questionnaires or interview except for body mass index (BMI) where height and weight were directly measured. Categorized, the variables included: age at blood draw (<41, 41-50, 51-60, 61-70, >70 years) , BMI (<18.5, ≥30 kg/m 2 ), smoking (never, former, current), pack years (≤11, 12-19, 20-31, >31) , age at menarche (<12, 12, 13, 14, >14) , OC use (never/ever), OC duration (≤2, >2-5, >5-10, >10 years), number (0, 1, 2, 3, 4+) and timing of pregnancies, age at first birth (<20, 20-24, 25-29, ≥30) , age at last birth (<25, 25-29, 30-34, ≥35) , years since last birth (<21, 21-27, 28-32, >32 years), hysterectomy, oophorectomy, family history of breast cancer, age at menopause (<46, 47-49, 50-51, 52-53, >53) , and HRT use (postmenopausal never used HRT, ≤2.5 years, >2.5 years). The number of ovulatory cycles was estimated by calculating years between menarche and current age or age at menopause (if postmenopausal) and subtracting time using oral contraceptives, pregnant, or breastfeeding. Those missing an exposure of interest were excluded from analyses for that exposure.
Laboratory Methods
Assays were performed at the Brigham and Women's Hospital Laboratory of Genital Tract Biology using a multiplex platform (Meso Scale Discovery, MSD). Laboratory personnel were blind to case-control and quality-control sample status. Methods related to the measurement of CA125 and CA15.3 were previously described(23). Similar batching rules used for the mucin antigens were employed for the mucin antibodies; i.e. keep matching pairs together and as many from the same center as possible with at least 6 QC samples. purified from human breast and ovarian cancer cell lines (Meridian Life Sciences Inc., Memphis, TN) were coated on multi-spot plates. The assays included blocking with a blocking buffer for 1h followed by wash; 2h incubation with samples at multiple dilutions followed by PBS/0.05% Tween-20 wash; detection of human IgG1 bound to the specific protein spots with MSD sulfoTag-labeled antibodies (1µg/ml) for 2h; washing and adding read buffer followed by detection of electro-chemiluminescence (ECL) using an MSD Imager 2400. Split aliquots of this pool were tested at the same dilutions as the test samples on each assay plate and served to assess interbatch variation. Coefficients of variation were calculated using measurements from blinded aliquots. Average intra-plate CVs were 14% for anti-CA125, 11% for anti-CA15.3, and the interplate CVs were 35% and 31%, respectively.
Statistical analyses
To account for batch-to-batch variation, we recalibrated antibodies to have a comparable distribution to an average batch according to methods described by Rosner and colleagues(24).
Other than batch number, no other variables were used in the recalibration models. Anti-CA15.3
and anti-CA125 antibody levels were log-transformed (as were CA15.3 and CA125).
Correlation between antigens and antibodies was assessed using Spearman partial correlations adjusted for the study matching factors. April 16, 2018; DOI: 10.1158 /1055 for heterogeneity in antibody levels by menopausal status. To examine the associations between antibodies and ovarian cancer, we classified antibodies into quartiles based on the control distribution and calculated odds ratios and 95% confidence intervals (CI) using conditional logistic regression. In the conditional logistic regression analyses, we individually added each potential confounder to the model and examined the change in the OR estimate from the crude OR. The covariates examined were age at menarche, OC use, parity, hysterectomy, oophorectomy, duration of HRT use, BMI, and smoking status (using categories described above). The percent changes in the adjusted ORs from the crude ORs were minimal, ranging from 0-3%, therefore we present crude conditional logistic regression results. We evaluated risk associations separately for cases diagnosed within three years (to reflect early detection) and greater than three years (to reflect risk); these lag-time cutpoints were based on prior studies in the EPIC cohort(23) and by others (20, 26) . Finally, using median values as cutpoints, we cross classified participants as having high or low antibodies and antigens and examined the association between these biomarker combinations and ovarian cancer. We used the contrast test method to test whether the association between increasing antibodies and risk, and between antigen-antibody combination and risk, varied by histologic type(27). Analyses were conducted using SAS version 9.4 (Cary, NC). Statistical tests were two-tailed and significant at p<0.05.
Informed consent and data protection
All participants gave consent for future analyses of their blood samples in their written consent. Author Manuscript Published OnlineFirst on April 16, 2018; DOI: 10.1158 /1055 (Germany). Since the identity of subjects providing specimens was anonymous to Brigham and Women's Hospital (BWH) investigators, the research was declared exempt at BWH. Table 1 compares the characteristics of EOC cases and controls in this nested case-control study.
Results
Cases did not differ from controls in age at enrollment or menopausal status, but were more likely to be heavier, nulliparous, and to have never used oral contraceptives (and used oral contraceptives for a shorter duration). Concentrations of anti-CA15.3 antibodies by epidemiologic variables in all, premenopausal, and postmenopausal controls are shown in Table   2 . Among postmenopausal women, we observed higher anti-CA15.3 antibodies with older age at baseline (P trend =0.04). Overall, anti-CA15.3 antibodies were lower among women with higher BMI (P trend =0.03) and current smoking (P<0.0001). Among current smokers, more pack-years were associated with lower anti-CA15.3 antibodies (P trend =0.002). Among women premenopausal at baseline, ever versus never use of OCs was associated with lower anti-CA15.3 antibodies (P=0.05); and higher number of ovulatory cycles was associated with a trend for lower anti-CA15.3 antibodies (P trend =0.02). Among postmenopausal women, higher anti-CA15.3 antibodies were associated with later age at last birth (P trend =0.02), shorter interval since last birth (P trend =0.04), and longer duration of OC use (P trend =0.01). The difference in the trend in anti-CA15.3 antibody levels by duration and OC use between pre-and postmenopausal women was significant (P for heterogeneity = 0.03).
Similar to associations seen for anti-CA15.3 antibodies, current smoking was associated with lower anti-CA125 antibodies (P<0.0001), and among smokers, anti-CA125 levels declined with increasing pack-years (P trend =0.004) ( April 16, 2018; DOI: 10.1158 /1055 birth (P trend =0.002) and shorter interval since last birth (P trend =0.005) were associated with higher anti-CA125 antibodies. Among premenopausal women, duration of OC use was associated with a lower level of anti-CA125 antibodies when non-users were included in the referent nonexposed category.
Among cases, we observed no associations between tumor characteristics and antibody levels (Supplemental Table 1 ). When we evaluated all cross-sectional associations adjusting for the corresponding antigen concentration, results were unchanged. Other variables that were examined and found not to affect anti-mucin antibodies in either cases or controls included: miscarriage, hysterectomy or unilateral oophorectomy, family history of breast cancer, IUD use, and duration of HRT use. Information on tubal sterilization was not collected at all EPIC sites and data was too limited to evaluate this exposure.
We then evaluated quartiles of anti-CA15.3 and anti-CA125 antibodies and EOC risk in all subjects and subjects stratified by menopausal status at blood collection, histologic type of EOC, and time between blood collection and diagnosis (<3 years and ≥3 years) ( Table 4) . For mucinous EOC arising three or more years after baseline, trends for increased risk were found with both increasing anti-CA15.3 antibodies (P trend =0.02) and increasing anti-CA125 antibodies (P trend =0.05). Of borderline significance, there was a trend for higher levels of anti-CA15.3 antibodies to be associated with lower risk for serous EOC (P trend =0.06) that developed within 3 years of their blood draw. Levels of anti-CA15.3 in the fourth quartile were associated with an OR (and 95% CI) of 0.51 (0.27, 0.96) compared to women with levels in the first quartile. Author Manuscript Published OnlineFirst on April 16, 2018; DOI: 10.1158 /1055 median cutpoints in controls ( Table 5) . Although combining CA15.3 antigen levels with anti-CA15.3 antibody levels was not informative, combining CA125 levels with anti-CA125 antibody yielded several interesting findings. Relative to women with low concentrations of both markers, EOC risk overall was elevated for women with high CA125 levels regardless of anti-CA125 antibody levels, but only for disease arising within 3 years of blood draw. These effects were most apparent in postmenopausal women and those with serous or endometrioid EOC.
Conversely, a reduction in risk for all EOC, both in short and long-term risk was associated with low CA125 antigen and high anti-CA125 antibody. For women who developed serous EOC, the combination of low CA125 antigen and high anti-CA125 antibody was associated with an OR (and 95% CI) of 0.60 (0.40, 0.89) for disease that developed more than 3 years after blood draw.
Anti-CA15.3 and anti-CA125 antibodies were strongly correlated in cases (r=0.75, P<0.0001) and controls (r=0.75, P<0.0001. In all premenopausal EOC cases, there was a weak but significant inverse correlation between CA15.3 and anti-CA15.3 antibodies of -0.15 (P=0.04) that was strongest for premenopausal serous cases r=-0.34 (P=0.001). In all EOC cases, there was a weak but significant positive correlation between CA125 and anti-CA125 antibodies of 0.10 (P=0.004) that was strongest for mucinous tumors r=0.40 (P=0.01). Overall, no significant correlations were noted between anti-mucin antibodies and their corresponding antigen in controls ( Table 6 ).
Discussion
We examined levels of IgG1 anti-CA15.3 and IgG1 anti-CA125 antibodies in baseline specimens from women who went on to develop EOC and matched controls from the EPIC April 16, 2018; DOI: 10.1158 /1055 cohort. We sought to identify those epidemiologic factors in control subjects that were associated with anti-mucin antibody levels. Our general premise was that events known to increase (or decrease) EOC risk will be those that decrease (or increase) anti-CA15.3 or anti-CA125 antibody levels. Using both case and control participants, we then sought to determine whether anti-CA15.3 or anti-CA125 antibodies, either by themselves or considered in the context of the corresponding antigen, were associated with EOC risk.
Because of their importance as correlates of EOC risk, the effect of reproductive variables on antibody levels were of principal interest. Decreased EOC risk with increasing parity and duration of OC use are two consistent epidemiologic findings. No clear effect of higher parity on either anti-CA15.3 or anti-CA125 antibody levels was seen, although longer duration of OC use was associated with higher anti-CA15.3 antibody levels (P trend =0.01) in postmenopausal women.
There is clear evidence that a later age at last birth (and a shorter interval since last birth) lowers EOC risk (25). Among postmenopausal women, but not premenopausal women, we observed higher levels of both anti-CA15.3 and anti-CA125 antibodies to be associated with a later age at and shorter interval since last birth. These late reproductive events are clearly set for postmenopausal women but may not be for premenopausal controls in EPIC. Both observations suggest that anti-CA125 antibodies may be generated during pregnancy, as has been reported for anti-CA15.3(15) antibodies, and wane with time since pregnancy.
We observed that lower anti-CA15.3 antibodies were associated with a higher number of ovulatory cycles in control subjects who were premenopausal at blood donation. This observation confirms an inverse correlation between anti-CA15.3 antibodies and ovulatory cycles seen in two other independent studies (20, 21) and is again consistent with the proposition that low antibodies predict greater risk since an increasing number of estimated ovulatory cycles is associated with increasing EOC risk(28-30). On the other hand, La Vecchia etal(31) expressed doubts about disentangling independent effects of the components of the algorithm used to construct the estimate (i.e. age at menarche, number of pregnancies, duration of OC use or breastfeeding, and current age or age at menopause). Particularly for premenopausal women, current age is an obvious confounder since older women will have a greater number of potential ovulatory years than younger women. However, the association we observed between ovulatory cycles and anti-CA15.3 antibodies seen in the linear regression models included continuous age as an adjustment variable. That the association was confined to premenopausal women is compatible with the observation that ovulatory cycles are a stronger predictor of EOC risk in premenopausal women than in postmenopausal women(30). Indeed, Purdie et al. proposed that more ovulations during ages 20-29 were the strongest predictor of greater EOC risk(29).
The lack of association between ovulatory cycles and anti-CA15.3 antibodies in postmenopausal women in our study and weak correlation of ovulatory cycles with EOC risk in postmenopausal women in published studies could reflect poorer recall of early reproductive events in postmenopausal women. Alternatively, the transition to menopause may take several years during which anovulatory cycles are common; therefore, the assumption that ovulation occurs regularly until menopause would introduce error in calculating ovulatory cycles for postmenopausal women.
Age, BMI, and smoking were non-reproductive variables that influenced antibody levels. Anti-CA15.3 antibodies increased with older age and declined with higher BMI. The latter observation is compatible with the fact that high BMI may increase risk for EOC, as well as other CA15.3-expressing cancers including endometrial cancer and postmenopausal breast cancer(32). Current smoking was associated with both lower anti-CA15.3 and anti-CA125 antibodies and levels decreased further with increasing pack-years. Smoking does not appear to affect risk for EOC overall but is associated with increased risk of mucinous EOC(33, 34). The observation that smoking lowers anti-CA15.3 antibodies and increases risk for mucinous tumors fits with our hypothesis regarding how risk factors may operate; but not our hypotheses that higher levels of antibodies lowers the risk for EOC in general. This may relate to the uniqueness of mucinous tumors compared to the other subtypes.
Despite finding general support for our premise that anti-CA15.3 and anti-CA125 antibodies may correlate with risk factors for EOC, we found no evidence that, by themselves, they predicted risk for EOC overall; but they may predict risk for specific histologic types of EOC.
Thus, we found higher levels of both anti-CA15.3 and anti-CA125 antibodies were associated with higher risk for mucinous tumors developing three or more years after baseline, though our numbers for this rarer subtype were limited, especially cases developing mucinous tumor premenopausally. As mentioned above this finding is contrary to our original hypothesis that anti-mucin antibodies may decrease risk for EOC, but may be explained by the similarities of mucinous ovarian tumors to colorectal cancers (CRC) which have been described(35). This is of interest in that a study looking at the ability of MUC1 auto-antibodies to predict risk for CRC in prospective specimens from United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) found that elevated levels predicted greater risk for CRC with a lead time of at least 2 years(36).
In our study, we found a modest trend (P=0.06) for a greater level of anti-CA15.3 antibodies to be associated with lower risk for serous ovarian cancer developing within 3 years of baseline; but no effect on long-term risk. The ability of anti-CA15.3 antibodies to predict risk for EOC was previously addressed in the Nurses ' Health Studies(20) . This study excluded cases diagnosed within three years to focus on longer term risk. In the NHS, higher levels of anti-CA15.3 antibodies decreased EOC risk in women who were <64 at blood draw but increased risk for women who were > 64 at blood draw. We examined age 64 as a cutpoint for long-term risk in the current study, but did not confirm the NHS finding. In the NHS, antibodies against an unglycosylated tandem repeat were measured while antibodies against intact CA15.3 were measured in this study. The ability of anti-MUC1 antibodies to aid in the early detection of EOC overall was also addressed in the UKCTOCS study. In this study, antibodies were measured against various glycopeptide "pieces" of MUC1 and recombinant (unglycosylated) MUC1 containing the 16 tandem repeats. Antibody reactivity to MUC1 tandem repeat peptides or glycoforms did not differ between controls and EOC cases, nor cases with other MUC1-expressing cancers, including breast, lung, and pancreas(37).
Neither the NHS nor UKCTOCS examined the combined effect of antigen and antibody levels as done in this study. Several new findings emerged in the current study with respect to both short and long-term risk for EOC, primarily related to CA125 antigen and its antibody. High CA125 levels, regardless anti-CA125 antibody level, predicted increased short-term risk for all EOC, EOC arising postmenopausally, and serous EOC. This is not surprising since both EPIC(23) and other prospective studies(38,39) reported elevated CA125 is the strongest predictor of EOC development within a year of the blood draw, but diagnostic discrimination wanes rapidly with lag-times between blood collection and diagnosis of more than 1 to 2 years. Perhaps more important is our novel observation that the combination of low CA125 and high anti-CA125
antibodies lowers risk for all EOC in both the long and short-term and for serous EOC in the long-term. The contribution of anti-CA125 antibody levels to CA125 in early detection is explored more fully in a separate publication(40). Limitations of our study are that standards for anti-CA15.3 or anti-CA125 antibody assays have not been established both in terms of antigen epitope to be used and which phenotype, IgG or IgM, to measure. In particular, epitopes used may be based on unique peptide sequences or the whole protein in either glycosylated or unglycosylated forms. It has been postulated that mucin antigens shed by inflammatory or hormonal events may be less glycosylated than unshed mucins and more similar to mucins shed by a tumor, but precise differences are unclear as well as whether anti-mucin antibodies formed in response to tumor mucins differ from those formed from non-neoplastic events. It is also possible that complexes involving the mucin antigens and antibodies can form which could hide the mucin antigen from its detection assay and be relevant to EOC cases presenting with low CA125(41). Finally, results of these analyses should be considered in the context of the number of tests performed and possibility of chance findings, particularly for subgroup analyses in which numbers are limited.
In conclusion, we found some support for our premise that events known to increase (or decrease) EOC risk generally correlate with those that decrease (or increase) anti-CA15.3 or anti-CA125 antibody levels. Although by themselves, anti-mucin antibodies were not strongly associated with overall EOC, higher levels of both anti-CA15.3 and anti-CA125 were associated with greater longer term risk for mucinous EOC. This might reflect the similarities of mucinous tumors to CRC where higher anti-MUC1 antibodies predict greater, not lower, risk. Not surprisingly, high CA125 regardless of anti-CA125 antibodies predicted higher risk for EOC in the short-term especially for women who developed serous EOC. Notably, the combination of low CA125 and high anti-CA125 antibodies is associated with lower long-term risk for serous EOC; i.e. disease developing 3 or more years after baseline. The latter observation may be more useful in defining the role of CA125 in the pathogenesis of serous EOC and less so for -17-0744 improving early detection. Advancing this research will require a greater understanding of the biology and immunology of CA125 and CA15.3, the nature of the antibodies that develop against them, and how they interact with traditional risk factors for EOC.
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Cramer (17) 9304 (6256, 13836) 0.82 *Geometric means adjusted for matching factors, including study center (grouped by country), age at blood draw, fasting status, date and time of blood draw, menopausal status at blood draw, menstrual cycle phase for premenopausal women at blood draw, OC/HRT use at blood draw, length of follow up. HRT use adjusted for hysterectomy. Age at menarche, OC use, parity, ovulatory cycles, hysterectomy, oophorectomy, menopausal status, age at menopause, and HRT use additionally adjusted for BMI and smoking status. † Trend including nulliparous women and those who never used oral contraceptives. § Trend among parous women and OC users. ¶Time between menarche and menopause with time subtracted for oral contraceptive use, pregnancy and breastfeeding; categories based on quartile cutpoints 
Type of HRT
Never used HRT -- -- -- -- -- -- 778 (75) 7931 (6792, 9260) Ref. Estrogen alone -- -- -- -- -- -- 81 (8) 13562 (8121, 22648) 0.18 Estrogen + Progestin -- -- -- -- -- -- 177
